Study Group: Generic Pharmaceuticals Regulation Experts: Healthcare Consultants(?)
Council Members in this Study Group: 27
Request a survey with this Study Group
Leading Experts in this Study Group
Eric Gruff, PhD MBA
Principal
E4 Consulting
Eric Gruff, PhD, MBA, BS, is the Founder of E4 Consulting, which specializes in pharmaceutical development, regulatory affairs, and project and portfolio management. Dr. Gruff has over 16 years of experience in the pharmaceutical and biotech sector, including leadership roles at Pfizer, Agouron Pharmaceuticals,...
President/Owner
Doctors of Pharmacy, Inc.
David Zimmerman, PharmD, FASCP, is the President and an Independent Consultant of Doctors of Pharmacy, Inc. Dr. Zimmerman formerly served as the Director of Clinical Affairs at Employee Health Insurance Management, a pharmacy benefit manager. He has over 30 years of experience, specializing in pharmacy...
President
MindPharma
Aemad Aslam, BPharm, MBA, RPh, is the President of MindPharma, a pharmacy and retail strategy consulting group. Most recently, he has consulted with a PBM, Prime Therapeutics, in Texas, a subsidiary of Blue Cross Blue Shield. He also has served as an Executive Team Leader for Pharmacy at the Target...
President and Chief Executive Officer
Ground Zero Pharmaceuticals, Inc.
Evan Siegel, MPhil, PhD, is the President and Chief Executive Officer at the Ground Zero Pharmaceuticals, Inc., a regulatory affairs and product development consulting firm in California. He provides services in the strategic, regulatory, preclinical, clinical CMC and compliance areas for firms developing...
Joseph Bertino, Pharm.D.Independent Consultant
Bertino Consulting
Joseph Bertino, PharmD, is an Associate Professor of Pharmacology at Columbia University College of Physicians and Surgeons in New York. Through Bertino Consulting, he consults to the pharmaceutical industry in areas of infectious diseases, drug metabolism, and clinical pharmacology. Dr. Bertino's research...
Jim FarleyPresident
Cardinal Consulting and Training
Jim Farley is an Independent Consultant and Owner of Cardinal Consulting and Training. Formerly, Mr. Farley served as the Director of the Science Branch of Philadelphia District FDA. He has over 30 years of experience in pharmaceutical and pharmaceutical packaging industries with extensive experience...
Nailesh BhattManaging Director
Proximare, Inc.
Nailesh Bhatt is the Managing Director of Proximare, Inc., a leading strategy consulting firm that exclusively serves the pharmaceutical industry with offices in New Jersey and India. In this role, Mr. Bhatt works with senior pharmaceutical executives to develop and implement growth strategies for R&D,...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
The recent publication of new cases of pancreatitis that are occurring in patients taking Byetta (exenatide) can't be good for Amylin/Lilly. While Byetta and investigational GLP-1 analogs are still very viable therapeutics for Type 2 Diabetes, prescribers will have to reassess the risk-benefit ratio...
-Crestor sold 2.8 billion dollars in sales in the recent year, will this partnership result in long term exponential growth? -What are the implications for Crestor with generic simvastatin and with Lipitor going generic in the next few years? -Is a combination product going to bolster Crestor sales
The issues associated with expensive therapeutics are multifaceted and involve personal, professional and societal components. Value related to medical treatment is uniquely assessed by each individual with respect to his/her financial burden, overall lifestyle and quality of life, societal role,...
-The new code will limit all gifts and meals to healthcare professionals, thus reducing pharmaceutical representative contact time. -Medical education programs will follow guidelines established by professional education groups -The guidelines do not go far enough for sales representative-healthcare...
1. Sponsors need to be "squeaky clean" with respect to their assessment of signals of toxicity in drug develpment programs. 2. This assessment should be made at the preclinical and early clinical stages of the process, irrespective of political and financial considerations. 3. The per cent of failures...
GLG InstituteSM Seminars with this Study Group's Leading Experts(?)
Recent Seminars
Most Common Company Types:
- Consultancy, Pharma-Focused
- Academic Institution*
- Consultancy, Healthcare-Focused
- Individual/Small Consultancy
- Healthcare Management
- Academic Medical Center/Hospital or Clinic
- Laboratory, Independent
- Pharmaceuticals/Biotechnology Research Services
- Strategic Management
Most Common Job Types:
- President
- Principal
- Owner
- Consultant
- Professor
- Director
- Chief Executive Officer
- Physician - Attending Physician
- Managing Director
- Teaching Assistant
- Board Member
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms